288 related articles for article (PubMed ID: 21791651)
21. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
Koss CA; Natureeba P; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Clark TD; Achan J; Ruel T; Nzarubara B; Kamya MR; Havlir DV; Cohan D
J Acquir Immune Defic Syndr; 2014 Oct; 67(2):128-35. PubMed ID: 25072616
[TBL] [Abstract][Full Text] [Related]
22. Influence of short-course antenatal antiretroviral therapy on viral load and mother-to-child transmission in subsequent pregnancies among HIV-infected women.
French CE; Tookey PA; Cortina-Borja M; de Ruiter A; Townsend CL; Thorne C
Antivir Ther; 2013; 18(2):183-92. PubMed ID: 23475123
[TBL] [Abstract][Full Text] [Related]
23. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women.
Grosch-Woerner I; Puch K; Maier RF; Niehues T; Notheis G; Patel D; Casteleyn S; Feiterna-Sperling C; Groeger S; Zaknun D;
HIV Med; 2008 Jan; 9(1):6-13. PubMed ID: 18199167
[TBL] [Abstract][Full Text] [Related]
24. Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: experiences from a PMTCT program in western India.
Darak S; Darak T; Kulkarni S; Kulkarni V; Parchure R; Hutter I; Janssen F
AIDS Patient Care STDS; 2013 Mar; 27(3):163-70. PubMed ID: 23477457
[TBL] [Abstract][Full Text] [Related]
25. Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Venkatesh KK; Farhad M; Fenton T; Moodley D; Naik S; Nakabiito C; Fairlie L; Fowler MG; Stringer JSA; Chi BH
AIDS; 2019 Dec; 33(15):2403-2413. PubMed ID: 31764105
[TBL] [Abstract][Full Text] [Related]
26. Elevated Levels of Estradiol in Human Immunodeficiency Virus-Infected Pregnant Women on Protease Inhibitor-Based Regimens.
Balogun KA; Guzman Lenis MS; Papp E; Loutfy M; Yudin MH; MacGillivray J; Walmsley SL; Silverman M; Serghides L
Clin Infect Dis; 2018 Jan; 66(3):420-427. PubMed ID: 29020282
[TBL] [Abstract][Full Text] [Related]
27. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
[TBL] [Abstract][Full Text] [Related]
28. Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.
Tubiana R; Mandelbrot L; Le Chenadec J; Delmas S; Rouzioux C; Hirt D; Treluyer JM; Ekoukou D; Bui E; Chaix ML; Blanche S; Warszawski J;
Clin Infect Dis; 2013 Sep; 57(6):891-902. PubMed ID: 23766338
[TBL] [Abstract][Full Text] [Related]
29. The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby: is 'the more the merrier'?
Martin F; Taylor GP
J Antimicrob Chemother; 2009 Nov; 64(5):895-900. PubMed ID: 19706669
[TBL] [Abstract][Full Text] [Related]
30. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction.
Papp E; Mohammadi H; Loutfy MR; Yudin MH; Murphy KE; Walmsley SL; Shah R; MacGillivray J; Silverman M; Serghides L
J Infect Dis; 2015 Jan; 211(1):10-8. PubMed ID: 25030058
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review.
Pasley MV; Martinez M; Hermes A; d'Amico R; Nilius A
AIDS Rev; 2013; 15(1):38-48. PubMed ID: 23449228
[TBL] [Abstract][Full Text] [Related]
32. No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.
Souda S; Gaseitsiwe S; Georgette N; Powis K; Moremedi D; Iketleng T; Leidner J; Moffat C; Ogwu A; Lockman S; Moyo S; Mmalane M; Musonda R; Makhema J; Essex M; Shapiro R
J Acquir Immune Defic Syndr; 2013 Aug; 63(5):572-7. PubMed ID: 23542639
[TBL] [Abstract][Full Text] [Related]
33. High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana.
Powis KM; McElrath TF; Hughes MD; Ogwu A; Souda S; Datwyler SA; von Widenfelt E; Moyo S; Nádas M; Makhema J; Machakaire E; Lockman S; Essex M; Shapiro RL
J Acquir Immune Defic Syndr; 2013 Apr; 62(5):517-24. PubMed ID: 23344545
[TBL] [Abstract][Full Text] [Related]
34. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
; de Vincenzi I
Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
[TBL] [Abstract][Full Text] [Related]
35. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Chung MH; Kiarie JN; Richardson BA; Lehman DA; Overbaugh J; Kinuthia J; Njiri F; John-Stewart GC
Antivir Ther; 2008; 13(6):799-807. PubMed ID: 18839781
[TBL] [Abstract][Full Text] [Related]
36. Nucleoside reverse transcriptase inhibitor backbones and pregnancy outcomes.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group
AIDS; 2019 Feb; 33(2):295-304. PubMed ID: 30562172
[TBL] [Abstract][Full Text] [Related]
37. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?
Thorne C; Newell ML
Drug Saf; 2007; 30(3):203-13. PubMed ID: 17343429
[TBL] [Abstract][Full Text] [Related]
38. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
Thior I; Lockman S; Smeaton LM; Shapiro RL; Wester C; Heymann SJ; Gilbert PB; Stevens L; Peter T; Kim S; van Widenfelt E; Moffat C; Ndase P; Arimi P; Kebaabetswe P; Mazonde P; Makhema J; McIntosh K; Novitsky V; Lee TH; Marlink R; Lagakos S; Essex M;
JAMA; 2006 Aug; 296(7):794-805. PubMed ID: 16905785
[TBL] [Abstract][Full Text] [Related]
39. [Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmission].
Palacios R; Senise JF; Vaz MJ; Castelo A
Enferm Infecc Microbiol Clin; 2008; 26(7):411-5. PubMed ID: 18842235
[TBL] [Abstract][Full Text] [Related]
40. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
